The clinical results of the protein degradation combination therapy by Arvinas and Pfizer (PFE.US) are positive, with a clinical benefit rate for patients exceeding 62%.
Arvinas and Pfizer (PFE.US) today announced preliminary data from the ongoing Phase 1b clinical trial TACTIVE-U sub-study.
BofA Restarts Coverage of 11 Large-cap Biopharmas
Pfizer Options Spot-On: On December 10th, 241.35K Contracts Were Traded, With 3.46 Million Open Interest
Unusual Options Activity: AI, MSTR and Others Attract Market Bets, AI V/OI Ratio Reaches 249.3
Market Falls Wednesday, but Googles Chip Impresses | WST
Google's Quantum Chip Might Have Contacted Parallel Universes | Live Stock
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
Ginvest : a guiltless conscience company. What do I do with my 5000 shares?
10baggerbamm OP Ginvest : that's your decision with vaccines these companies are 100% exonerated under current laws in the United States you can't sue any vaccine manufacturers now maybe that will change with Kennedy I don't know I think there should be accountability at all levels.